GDD-3898 is under clinical development by Lipidio Pharmaceuticals and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GDD-3898’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GDD-3898 is under development for the treatment of nonalcoholic fatty liver disease, non-alcoholic steatohepatitis, Prader-Willi syndrome, antipsychotic drug-induced weight gain (AIWG), acne vulgaris and sebaceous hyperplasia. The drug candidate acts by targeting stearoyl-CoA desaturase (SCD-1). It is administered through topical route.
Lipidio Pharmaceuticals overview
Lipidio Pharmaceuticals is a healthcare company that focuses on advancing a molecule to treat diseases associated with excess body fat. It includes non-alcoholic steatohepatitis, Prader-Willi syndrome, and antipsychotic drug-induced weight gain. Lipidio Pharmaceuticals is headquartered in San Diego, California, the US.
For a complete picture of GDD-3898’s drug-specific PTSR and LoA scores, buy the report here.